Saturday 17 October 2026
Export CNTB’s income statement to Excel — free account
Connect Biopharma Holdings Limited Sponsored ADR
CNTB Healthcare Biotechnology
Connect Biopharma Holdings Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $64,000.00, down 99.8% from fiscal 2024. In the quarter to June 2026, revenue grew 296.6%, EPS fell 17.4%, free cash flow fell 23.5% and total debt fell 61.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.91
0.00
0.00%
Follow CNTB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | — | — | — | — | — |
Altman Z-Score |
(5.94) | 0.81 | — | — | — | — | — | — | — |
P/S ratio |
79.23 | 0.00 | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(22.77) | 3.74 | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | — | — | — | — | — | — |
Beneish M-Score |
681.78 | — | — | — | — | — | — | — | — |
P/Operating CF |
(13.95) | (32.86) | — | — | — | — | — | — | — |
P/B ratio |
3.74 | 0.83 | — | — | — | — | — | — | — |
Price to Tangible BV |
3.74 | 0.83 | — | — | — | — | — | — | — |
EV/Sales |
57.04 | 0.00 | — | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.25 | — | — | — | — | — | — | — |
EV/Operating CF |
(2.21) | 0.74 | — | — | — | — | — | — | — |
EV/FCF |
(2.19) | 0.71 | — | — | — | — | — | — | — |
Quick Ratio |
3.74 | 11.46 | 4.85 | 9.97 | 15.30 | 27.81 | 12.40 | 67.82 | — |
Current Ratio |
3.74 | 11.46 | 4.85 | 9.97 | 15.30 | 27.81 | 13.24 | 70.44 | — |
Net Debt/EBITDA |
0.77 | 4.30 | 1.73 | 1.29 | 2.72 | 5.21 | (2.62) | (2.13) | — |
Debt/Assets |
0.66% | 0.02% | 0.14% | 0.14% | 0.01% | 0.03% | 172.82% | 126.71% | 0.00% |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2.16) | (4.52) | — |
Asset Turnover |
0.00 | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.92 | 1.51 | 0.77 | 0.86 | 0.42 | 0.21 | 0.54 | 0.90 | — |
Capex/Depreciation |
(0.61) | (1.14) | 3.98 | (4.27) | (6.19) | (10.60) | 0.00 | 0.00 | — |
Interest Coverage |
— | — | (3,002.43) | (5,681.71) | (14,148.29) | (68.42) | (121.12) | (11.35) | — |
| (82.72%) | (16.14%) | (47.96%) | (54.96%) | (355.92%) | 119.48% | 79.58% | 37.93% | — | |
| (70.51%) | (13.67%) | (41.21%) | (50.78%) | (89.64%) | (108.69%) | (40.82%) | (35.21%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | (1,401.74%) | (1,355.35%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(134.91%) | (16.89%) | (61.17%) | (81.37%) | (76.93%) | (75.97%) | (50.17%) | (18.05%) | — |
Average Days of Receivables |
37,566.48 | 45.61 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
59,059.38% | 112.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
31,781.25% | 73.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
5,821.88% | 25.84% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Graham Net Nets |
0.23 | 1.15 | — | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | — | — | — | — | — | — | — |
Earnings Yield |
(35.46%) | (80.59%) | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(32.90%) | (32.36%) | — | — | — | — | — | — | — |
Revenue per Share |
0.00 | 0.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.92) | (0.43) | (0.87) | (1.84) | (1.64) | (0.86) | (0.23) | (0.18) | — |
Capex per Share |
(0.01) | (0.01) | 0.05 | (0.08) | (0.08) | (0.08) | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(0.93) | (0.44) | (0.81) | (1.92) | (1.71) | (0.94) | (0.23) | (0.18) | — |
Cash per Share |
0.80 | 1.70 | 2.15 | 2.77 | 5.13 | 5.27 | 0.85 | 1.09 | — |
Shareholders Equity per Share |
0.75 | 1.67 | 1.84 | 2.86 | 5.22 | (5.28) | (0.74) | (0.32) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.75 | 1.67 | 1.84 | 2.86 | 5.22 | (5.28) | (0.74) | (0.32) | — |
Free Cash Flow |
(51.64) | (24.36) | (44.88) | (105.92) | (89.43) | (27.96) | (13.06) | (10.43) | — |
Working Capital |
37.32 | 88.50 | 97.26 | 140.16 | 257.14 | 156.14 | 48.15 | 64.00 | — |
Capital Expenditures |
(0.43) | (0.75) | 2.86 | (4.40) | (3.96) | (2.34) | (0.16) | (0.18) | — |
Net Current Asset Value |
36.83 | 87.84 | 96.68 | 139.26 | 256.33 | (161.38) | (44.23) | (19.66) | — |
EV/EBIT |
0.00 | 0.00 | — | — | — | — | — | — | — |
Capex to Sales |
6.75 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Price to Operating Income |
0.00 | 0.00 | — | — | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.18 | 0.16 | 0.17 | 0.21 | 0.07 | 0.21 | 0.23 | 0.21 | — |
Cash ROIC |
(59.57%) | (13.11%) | (20.40%) | (34.15%) | (16.56%) | 12,264.91% | (13.28%) | (8.17%) | — |
Accounts Receivable Turnover |
0.01 | 6.94 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.05 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10,447.05 | 1,915.29 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
4.92 | 3.75 | 3.81 | 5.39 | 6.29 | 6.29 | — | — | — |
Average Payables |
1.15 | 1.28 | 7.07 | 12.34 | 8.26 | 3.52 | 1.89 | 1.89 | — |
Average Assets |
78.68 | 114.33 | 150.69 | 232.53 | 228.66 | 109.88 | 59.78 | 33.03 | — |
Average Common Equity |
67.07 | 96.83 | 129.49 | 214.87 | 57.59 | (99.95) | (30.67) | (30.67) | — |
Columns are period end dates